Literature DB >> 35505036

Combination of Photodynamic Therapy and Therapeutic Vaccination.

Jan Willem Kleinovink1, Ferry Ossendorp2.   

Abstract

Tumor ablation by photodynamic therapy (PDT) results in a strong reduction in tumor mass and can lead to improved recognition of tumor cells by the immune system. This supports combinations of PDT and immunotherapy for the treatment of advanced tumors. Therapeutic vaccination is a tumor-specific type of cancer immunotherapy that aims to directly strengthen the immune response against tumor antigens. In this chapter, we describe the combination of PDT and therapeutic vaccination using a peptide tumor antigen vaccine.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antigen; Cancer; Immunotherapy; PDT; Peptide; Photodynamic therapy; SLP; T cells; Tumor; Vaccination

Mesh：

Substances：

Year:  2022        PMID： 35505036     DOI： 10.1007/978-1-0716-2099-1_31

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  9 in total

1.  Cancer vaccines generated by photodynamic therapy.

Authors:  Mladen Korbelik
Journal:  Photochem Photobiol Sci       Date:  2011-01-24       Impact factor: 3.982

Review 2.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

3.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

Authors:  K Y Lin; F G Guarnieri; K F Staveley-O'Carroll; H I Levitsky; J T August; D M Pardoll; T C Wu
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

4.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

Authors:  Gemma G Kenter; Marij J P Welters; A Rob P M Valentijn; Margriet J G Lowik; Dorien M A Berends-van der Meer; Annelies P G Vloon; Farah Essahsah; Lorraine M Fathers; Rienk Offringa; Jan Wouter Drijfhout; Amon R Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Sjoerd H van der Burg; Cornelis J M Melief
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

5.  Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.

Authors:  Gemma G Kenter; Marij J P Welters; A Rob P M Valentijn; Margriet J G Lowik; Dorien M A Berends-van der Meer; Annelies P G Vloon; Jan W Drijfhout; Amon R Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Rienk Offringa; Sjoerd H van der Burg; Cornelis J M Melief
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

6.  Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors.

Authors:  Jan Willem Kleinovink; Pieter B van Driel; Thomas J Snoeks; Natasa Prokopi; Marieke F Fransen; Luis J Cruz; Laura Mezzanotte; Alan Chan; Clemens W Löwik; Ferry Ossendorp
Journal:  Clin Cancer Res       Date:  2015-11-06       Impact factor: 12.531

7.  HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.

Authors:  Mariette I E van Poelgeest; Marij J P Welters; Edith M G van Esch; Linda F M Stynenbosch; Gijs Kerpershoek; Els L van Persijn van Meerten; Muriel van den Hende; Margriet J G Löwik; Dorien M A Berends-van der Meer; Lorraine M Fathers; A Rob P M Valentijn; Jaap Oostendorp; Gert Jan Fleuren; Cornelis J M Melief; Gemma G Kenter; Sjoerd H van der Burg
Journal:  J Transl Med       Date:  2013-04-04       Impact factor: 5.531

Review 8.  Vaccine adjuvants as potential cancer immunotherapeutics.

Authors:  Burcu Temizoz; Etsushi Kuroda; Ken J Ishii
Journal:  Int Immunol       Date:  2016-03-22       Impact factor: 4.823

Review 9.  Adjuvants for peptide-based cancer vaccines.

Authors:  Hiep Khong; Willem W Overwijk
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.